system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: 5-Methylcytosine, Carcinoma, Hepatocellular, Cytosine, DNA Methylation, Female, Hepatectomy, Humans, Isocitrate Dehydrogenase, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local, Prognosis, Proportional Hazards Models, Retrospective Studies, Treatment Outcome.
user
Is high expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 associated with favorable prognosis after curative resection of hepatocellular carcinoma? Context: The expression of 5-hydroxymethylcytosine (5-hmC) and isocitrate dehydrogenase 2 (IDH2) is frequently downregulated in numerous cancers. 5-hmC and IDH2 expression in hepatocellular carcinoma (HCC) has yet to be determined. The immunohistochemical expression of 5-hmC and IDH2 were analyzed in tissue microarrays containing samples from 646 patients who had undergone hepatectomy for histologically proven HCC. The prognostic value of 5-hmC and IDH2 were evaluated by Cox regression and Kaplan-Meier analyses. We discovered that low 5-hmC and IDH2 expression was associated with malignant behaviors. Low 5-hmC or IDH2 expression alone and combined 5-hmC and IDH2 expression were associated with lower overall survival (OS) rates and higher cumulative recurrence rates. Multivariate analysis indicated that 5-hmC or IDH2 and 5-hmC/IDH2 were independent prognostic indicators for OS and time to recurrence (TTR), which was confirmed in an independent validation cohort.
assistant
5-hmC and IDH2 correlate with less aggressive tumor behavior in HCC. When 5-hmC and IDH2 are considered together, they serve as a prognostic marker in patients with surgically resected HCCs. Final Decision: yes